Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.48 |
| ▸ | CCR2 | P41597 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.45 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
| ▸ | BID | P55957 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.39 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19921325 | 0.90 | L3MBTL1 (0.54) | ALDH1A1LMNAMAPTCYP2C19PTGDR2 | |
| SCHEMBL27700600 | 0.89 | ALDH1A1 (0.53) | ALDH1A1LMNAMAPTCYP2C19PTGDR2 | |
| SCHEMBL1772350 | 0.89 | LMNA (0.53) | ALDH1A1LMNAMAPTCYP2C19PTGDR2 | |
| SCHEMBL14053495 | 0.87 | ALDH1A1 (0.55) | ALDH1A1LMNAMAPTCYP2C19PTGDR2 | |
| SCHEMBL31219358 | 0.86 | ALDH1A1 (0.50) | ALDH1A1LMNAMAPTCYP2C19PTGDR2 | |
| SCHEMBL18181213 | 0.86 | ALDH1A1 (0.50) | ALDH1A1LMNAMAPTCYP2C19PTGDR2 | |
| SCHEMBL1964363 | 0.83 | ALDH1A1 (0.47) | ALDH1A1LMNAMAPTCYP2C19PTGDR2 | |
| SCHEMBL10003716 | 0.83 | NOD2 (0.60) | ALDH1A1LMNAMAPTCYP2C19PTGDR2 | |
| SCHEMBL10003006 | 0.83 | ALDH1A1 (0.47) | ALDH1A1LMNAMAPTCYP2C19PTGDR2 | |
| SCHEMBL1963733 | 0.83 | ALDH1A1 (0.47) | ALDH1A1LMNAMAPTCYP2C19PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737445-A1 | NOVEL SATURATED HETEROCYCLE-SUBSTITUTED HETEROARYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF | Korea Institute of Science and Technology (KR) | 2026-05-06 | — | — | EP | disclosed |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| WO-2025005367-A1 | NOVEL SATURATED HETEROCYCLE-SUBSTITUTED HETEROARYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF | 한국과학기술연구원 | 2025-01-02 | — | — | WO | disclosed |
| CN-113727972-B | Novel hydrazone derivatives having terminal amine groups substituted with aryl or heteroaryl groups and use thereof | 韩国科学技术研究院 | 2024-12-27 | — | — | CN | disclosed |
| US-20220396553-A1 | NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2022-12-15 | — | — | US | disclosed |
| CN-113727972-A | Novel hydrazone derivatives in which terminal amino group is substituted with aryl or heteroaryl group, and use thereof | 韩国科学技术研究院 | 2021-11-30 | — | — | CN | disclosed |
| EP-3901139-A1 | NOVEL HYDRAZONE DERIVATIVE WITH ARYL OR HETEROARYL GROUP SUBSTITUTED AT TERMINAL AMINE GROUP THEREOF AND USE THEREOF | Korea Institute of Science and Technology (KR) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020130214-A1 | NOVEL HYDRAZONE DERIVATIVE WITH ARYL OR HETEROARYL GROUP SUBSTITUTED AT TERMINAL AMINE GROUP THEREOF AND USE THEREOF | 한국과학기술연구원 | 2020-06-25 | — | — | WO | disclosed |
| EP-3286166-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2020-05-13 | — | — | EP | disclosed |
| US-10221129-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2019-03-05 | — | — | US | disclosed |
| US-20080280946-A1 | Azaindole-Derivatives As Factor Xa Inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-11-13 | — | — | US | disclosed |
| US-7317027-B2 | 1-substituted 2-carboxamide derivatives of fused ring pyrroles, especially pyrrolo[2,3-b]pyridines and pyrrolo[3,2-b]pyridines, e.g., 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-01-08 | — | — | US | disclosed |
| US-20070299091-A1 | Azaindole Carboxamides | GMEINER PETER | 2007-12-27 | — | — | US | disclosed |
| CN-100347172-C | Azaindole-derivatives as factor Xa inhibitors | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-11-07 | — | — | CN | disclosed |
| CN-101056878-A | Azaindole carboxamides | SCHVARZ PHARMA AG (DE) | 2007-10-17 | — | — | CN | disclosed |
| CN-1791601-A | azaindole derivatives as factor Xa inhibitors | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-06-21 | — | — | CN | disclosed |
| EP-1636226-A1 | AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-03-22 | — | — | EP | disclosed |
| US-20050009828-A1 | Azaindole-derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND (DE) | 2005-01-13 | — | — | US | disclosed |
| WO-2004101563-A1 | AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | disclosed |
| EP-1479680-A1 | Azaindole derivatives as Factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009828-A1 | Azaindole-derivatives as factor Xa inhibitors | F12, F5, F11 | ALDH1A1 2292/4885LMNA 295/4885MAPT 4852/4885 |
| US-20070299091-A1 | Azaindole Carboxamides | TPH1, TPH2, HTR1A | ALDH1A1 505/4885LMNA 4225/4885MAPT 2144/4885 |
| US-20080280946-A1 | Azaindole-Derivatives As Factor Xa Inhibitors | F12, F5, F11 | ALDH1A1 2202/4885LMNA 279/4885MAPT 4839/4885 |
| US-10221129-B2 | Inhibitors of human immunodeficiency virus replication | EIF2AK2, POLR2E, POLR2H | ALDH1A1 2912/4885LMNA 3667/4885MAPT 1607/4885 |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | ABL1, TH, CYP3A43 | ALDH1A1 1008/4885LMNA 4524/4885MAPT 3633/4885 |
| US-20220396553-A1 | NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF | AANAT, NAT1, HNMT | ALDH1A1 402/4885LMNA 4118/4885MAPT 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.